The EPS miss is not material for a pre-revenue biotech; the key catalysts are the ATR 1072 IND clearance and the BMS milestone. Monitor enrollment updates for Corventis and any further BMS collaboration milestones, as these are the primary value drivers.
Price Chart
Executive Summary
Atrium Therapeutics reported Q2 2026 collaboration revenue of $3.0M, a net loss of -$1.18 per share, and highlighted FDA clearance of its IND for ATR 1072 in PRKAG2 syndrome. The EPS miss of -51.6% vs consensus is largely a mechanical artifact of the company's pre-revenue, clinical-stage status and does not reflect business deterioration. The stock's move will be driven by pipeline progress (IND clearance, BMS milestone) rather than the earnings surprise itself.
Key Financial Metrics
Key Facts
- Collaboration revenue was $3.0M for Q2 2026, primarily from the BMS collaboration.
- Net loss per share was -$1.18, compared to -$0.75 in Q2 2025.
- Cash, cash equivalents, and short-term investments were $263.9M as of June 30, 2026, sufficient to fund operations through mid-2028.
- FDA cleared IND for ATR 1072; first participant enrollment in Corventis Phase 1/2 trial expected by end of 2026.
- Achieved a second milestone payment of $15M from Bristol Myers Squibb in August 2026.
Financial Impact
EPS miss of -51.6% vs consensus on a small absolute base; no revenue surprise as consensus was $500K and actual collaboration revenue was $3.0M (not directly comparable due to BMS milestone structure).
Risk Factors
- Clinical trial enrollment delays for Corventis.
- Dependence on BMS collaboration for near-term revenue.
- Pre-revenue status with no approved products; cash runway only through mid-2028.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-prn-302851394 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | Press Release | $8.00 | awaiting T+5 | — | $8.05 (+0.63%) |
Oct 9, 2026 17d ago | 8-K/A | $8.40 $7.67 | ▼ −8.69% | ▼ −6.72% | $8.05 (−4.17%) |
Oct 8, 2026 18d ago | 8-K | $8.26 $7.82 | ▲ +5.33% | ▲ +5.05% | $8.05 (+2.54%) |
Sep 21, 2026 5w ago | Press Release | $9.22 $8.42 | ▼ −8.68% | ▼ −7.49% | $8.05 (−12.69%) |
Aug 20, 2026 9w ago | Press Release | $13.20 $13.64 | ▲ +3.33% | ▲ +2.86% | $8.05 (−39.02%) |
Aug 13, 2026 10w ago | 8-K | $12.84 $13.20 | ▲ +2.80% | ▲ +4.17% | $8.05 (−37.31%) |
Aug 13, 2026 10w ago | Press Release | $12.84 $13.20 | ▲ +2.80% | ▲ +4.17% | $8.05 (−37.31%) |
Jul 20, 2026 13w ago | Press Release | $12.29 $11.57 | ▼ −5.86% | ▼ −4.63% | $8.05 (−34.50%) |
Jul 14, 2026 14w ago | 8-K | $12.30 $12.17 | ▼ −1.06% | ▼ −0.08% | $8.05 (−34.55%) |
May 14, 2026 23w ago | 8-K | $13.23 $13.09 | ▼ −1.06% | ▼ −2.02% | $8.05 (−39.15%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers